ArticleJournal of cellular and molecular medicine2012
Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells.
Article in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- Resveratrol in Combination Therapy: Mechanisms and Limitations of Resveratrol in Cancer, Regeneration, and Chronic DiseaseIranian biomedical journal · 2026Review
- Mesenchymal stromal cells for the treatment of Alzheimer's disease: Strategies and limitations.Frontiers in molecular neuroscience · 2022Review
- Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection.Pharmaceutical research · 2021Review
- The Potential Properties of Natural Compounds in Cardiac Stem Cell Activation: Their Role in Myocardial Regeneration.Nutrients · 2021Review
- Review
- Resveratrol rescues TNF‑α‑induced inhibition of osteogenesis in human periodontal ligament stem cells via the ERK1/2 pathway.Molecular medicine reports · 2020Article
- Protective Effects of Resveratrol Supplementation on Contusion Induced Muscle Injury.International journal of medical sciences · 2020Article
- Adult Cardiac Stem Cell Aging: A Reversible Stochastic Phenomenon?Oxidative medicine and cellular longevity · 2019Review
- Resveratrol improves human umbilical cord-derived mesenchymal stem cells repair for cisplatin-induced acute kidney injury.Cell death & disease · 2018Article
- Resveratrol promotes hUC-MSCs engraftment and neural repair in a mouse model of Alzheimer's disease.Behavioural brain research · 2018Article
- Resveratrol counteracts bone loss via mitofilin-mediated osteogenic improvement of mesenchymal stem cells in senescence-accelerated mice.Theranostics · 2018Article
- Cardioprotective effect of indirubin in experimentally induced myocardial infarction in wistar rats.International journal of clinical and experimental pathology · 2017Article
- Resveratrol pretreatment attenuates injury and promotes proliferation of neural stem cells following oxygen-glucose deprivation/reoxygenation by upregulating the expression of Nrf2, HO-1 and NQO1 in vitro.Molecular medicine reports · 2016Article
- Resveratrol Enhances Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells through Inhibiting Canonical WNT Signal Pathway and Enhancing Serum Response Factor-miR-1 Axis.Stem cells international · 2016Article
- Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance.Oxidative medicine and cellular longevity · 2016Review
- Cell Therapy in Ischemic Heart Disease: Interventions That Modulate Cardiac Regeneration.Stem cells international · 2016Review
- c-kit(+) cells: the tell-tale heart of cardiac regeneration?Cellular and molecular life sciences : CMLS · 2015Review
- Cross effects of resveratrol and mesenchymal stem cells on liver regeneration and homing in partially hepatectomized rats.Stem cell reviews and reports · 2015Article
- Enzymatic Biosynthesis of Novel Resveratrol Glucoside and Glycoside Derivatives.Applied and environmental microbiology · 2014Article
- Redox signaling in cardiac renewal.Antioxidants & redox signaling · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major problem in stem cell therapy includes viability and engraftment efficacy of stem cells after transplantation. Indeed, the vast majority of host-transfused cells do not survive beyond 24-72 hrs. To increase the survival and engraftment of implanted cardiac stem cells in the host, we developed a technique of treating these cells with resveratrol, and tested it in a rat model of left anterior descending (LAD) occlusion. Multi-potent clonogenic cardiac stem cells isolated from rat heart and stably transfected with EGFP were pre-treated with 2.5 μM resveratrol for 60 min. Rats were anaesthetized, hearts opened and the LAD occluded to induce heart attack. One week later, the cardiac reduced environment was confirmed in resveratrol treated rat hearts by the enhanced expression of nuclear factor-E2-related factor-2 (Nrf2) and redox effector factor-1 (Ref-1). M-mode echocardiography after stem cell therapy, showed improvement in cardiac function (left ventricular ejection fraction, fractional shortening and cardiac output) in both, the treated and control group after 7 days, but only resveratrol-modified stem cell group revealed improvement in cardiac function at the end of 1, 2 and 4 months time. The improvement of cardiac function was accompanied by enhanced stem cell survival and engraftment as demonstrated by the expression of cell proliferation marker Ki67 and differentiation of stem cells towards the regeneration of the myocardium as demonstrated by the expression of EGFP up to 4 months after LAD occlusion in the resveratrol-treated stem cell group. Expression of stromal cell-derived factor and myosin conclusively demonstrated homing of stem cells in the infarcted myocardium, its regeneration leading to improvement of cardiac function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.